The preventative drug is aimed at those suffering four migraines a month

A new drug that could help some migraine sufferers is one step closer to approval.

The European Medicines Agency has recommended granting a marketing authorisation for Emgality.

That will now be considered by the European Commission.

It is a preventative drug and is intended for use by those suffering at least 4 migraines a month.

Dublin MEP Brian Hayes says a final decision on approval for the drug could be just months away.